Background Topical treatment of mild to moderate psoriasis is first-line treatment and exhibits varying degrees of suc-
Introduction
Psoriasis is a chronic inflammatory disease with a prevalence ranging from below 0.5% to 4-8.5%. 1 In approximately onethird of patients with extensive disease, skin lesions are accompanied by joint involvement presenting as psoriatic arthritis. 2 Plaque type psoriasis is the most common form of psoriasis affecting either localized areas (face, scalp, nails, genitals) or generalized symmetrical body regions with disease severity ranging from mild through moderate to severe. The majority of patients are categorized as having mild to moderate disease severity and topical treatment, as monotherapy, is a mainstay in psoriasis treatment. Topical treatment is sufficient in the majority of these patients, 3 whereas systemic treatment including biologics is used to treat moderate to severe disease as well as psoriatic arthritis. 4 Multiple topical therapies are available including topical corticosteroids, vitamin D analogues, calcineurin inhibitors, retinoids, dithranol (antralin), tars, balneotherapy, phototherapy and salicylic acid. In many countries, Germany, the United Kingdom (UK), the United States (US) among others, guidelines currently exist for topical treatment of psoriasis; 3, 5, 6 however, no international consensus on topical treatment of psoriasis is available. The World Health Organization recently recognized psoriasis as a chronic, non-communicable, painful, disfiguring and disabling disease for which there is no cure. 7 In this report, WHO also acknowledged that treatment access and the use of healthcare services are important determinants of health. Knowledge about availability of different treatment options is therefore important in addressing disease burden on a global scale. Access to health care can be described by availability, affordability and acceptability. [8] [9] [10] [11] [12] Availability of health care implies the physical presence of medication as well as access to physicians, 8 but there is only limited knowledge about differences in patient access to topical treatment for psoriasis between countries.
Whether limited access to specific treatments impacts the patient's health status is not known; it is commonly accepted that low or no access to specific drugs may be an obstacle to improve the health status for the individual patient as well as for the whole population in a country. Therefore, increased knowledge about the availability of topical therapies and how they are used across different countries and regions of the world is warranted.
Psoriasis severity is categorized into either mild, moderate or severe disease often based upon the percentage of body surface area (BSA) affected. The categories of psoriasis are defined as mild (BSA < 3%), moderate (BSA 3-10%) and severe (BSA > 10%) with treatment determined by disease severity classifications. There are challenges with this classification system; however, for the purpose of our survey, we have elected to use these categories to assess how disease severity directs usage of topical treatment.
Councillors from the International Psoriasis Council (IPC) established a working group with the overall goal to examine the landscape of topical therapies. With the aim to describe and analyse cross-regional variations in the use of topical therapies, a survey was conducted among international psoriasis experts around the world. This report focuses on results obtained from the first and second section of the questionnaire describing the availability of topical medications and how the use of these, as monotherapy and in combination with a second topical or other therapy, is influenced by disease severity.
Methods

Study design
The study was conducted as an observational cross-sectional study. In early 2015, a questionnaire was distributed electronically to a total of 99 councillors from the IPC, representing 26 countries around the world. The questionnaire was developed by an IPC working group with technical assistance from Question Mark Media, who was also responsible for collecting and gathering data.
The questionnaire consisted of four sections, each uncovering different aspects of topical therapies and use in psoriasis treatment. Part 1 of the survey includes: 1 Access to treatment/physician settings 2 Influence of disease severity (BSA) on the use of topicals This report focuses on results obtained from Part 1 of the questionnaire describing the availability of topical medications and how the use of these, as monotherapy and in combination with a second topical or other therapy, is influenced by disease severity.
The questionnaire included both multiple response questions (select all that apply), where each option was treated as a binary variable, as well as questions with categorical and continuous variables. The questionnaire was distributed twice, and data from a total of 45 respondents were obtained. Inclusion criterion for this study was a completely or partially answered questionnaire.
Exclusion criterion was failure to respond prior to the deadline (on this basis, two respondents have been excluded).
Data analysis
All data collected through the questionnaire were manually entered and then processed using SPSS. To validate data entry, two independent data samples from four respondents (9.3%) were randomly selected and cross-checked for discrepancies between the responses collected through the questionnaire and data entered into SPSS. One single discrepancy was found which corresponds to an error frequency of 1/3680.
In a subsequent analysis, statistical frequency analysis was performed according to each question. Respondents with missing answers were excluded. For some questions, further analysis was carried out including country and region as variables to identify possible correlations, but no analysis for statistical significance was performed. The latter was considered to be of less importance as the purpose of this study was mainly descriptive.
Results
A total of 20 different countries are represented in the survey, with the number of respondents from each country ranging from 1 to 7. Regionally, Europe is represented best with a total of 18 respondents, whereas Asia, Australia and Africa are only represented by a few (Fig. 1) .
All respondents were councillors of the IPC and are considered experts on psoriasis with special interest in the disease and broad experience in treating psoriasis patients. Clinical practice pattern data show that respondents (data from 29 respondents) treated between 15 and 300 psoriasis patients per month with a mean of 108 patients. The vast majority of respondents were dermatologists working either exclusively through the public healthcare system (PHCS) (34.9%), with private patients and health insurance (HI) patients (32.6%) or part-time working through the PHCS and part-time working with private patients and HI patients (27.9%). All respondents from the USA and the majority of respondents from Canada were dermatologists working with private patients and HI patients. This was also the case for each respondent from Germany and India (private patients exclusively). In most of the remaining countries, the majority of respondents were either working exclusively or part-time through the PHCS ( 
Availability of topical medications
Minimal variation was found, among respondents and by region, regarding commercial availability of topical corticosteroids, calcineurin inhibitors, vitamin D analogues and potent corticosteroids in combination with vitamin D analogues ( Table 1) . By contrast, we found variation in the availability of tars, topical retinoids, dithranol and balneotherapy. Only 67.4% of respondents answered that topical retinoids were commercially available in their country. When country was included as a variable, the data suggest that topical retinoids were commercially available in 11 of the 20 countries, whereas topical retinoids were not available in seven countries. Within two countries, differences among the answers of respondents were found (data not shown).
The influence of disease severity on the use of topical therapy
To examine how disease severity (measured as BSA involvement), influences the use of topical therapy, both as monotherapy and in combination with other therapies, respondents were asked a number of questions concerning their use of topicals in certain situations.
The percentage of respondents who use the topicals listed in Table 1 , as well as emollients, as first-line monotherapy, decreases with increasing BSA involvement ( Table 2) . With a BSA below 3%, 100% of the respondents reported that topical therapy is used as first-line monotherapy. The number of respondents reporting use of topical treatment as first-line monotherapy decreased with increasing BSA. Only 27.9% reported use of topical therapy as first-line monotherapy in patients with as BSA above 10% (Table 2) .
If topical therapy is used as monotherapy, we found that for both BSA < 3% and BSA between 3% and 10%, the two most frequently used first-line drugs are potent topical corticosteroids in combination with vitamin D analogues or potent topical corticosteroids alone (Table 3) . When comparing BSA between 3% and 10% to BSA < 3%, a decrease is seen in the percentage of respondents who use mild or potent topical corticosteroids as well as calcineurin inhibitors. This suggests that these topicals are more commonly used as first-line drugs when treating patients with mild disease. Conversely, the percentage of respondents using potent topical corticosteroids in combination with vitamin D analogues increases in the group of patients with a BSA between 3% and 10% compared with patients with a BSA < 3% (Table 3) .
For severe disease, BSA > 10%, more than one-third (38.1%) of the respondents, answered that this question was not relevant, possibly due to the limited use of topical therapy as first-line monotherapy in this situation (Table 2) . Among the remaining respondents, the most frequently used first-line therapy was Psoriasis; Access and usage of topical therapy potent topical corticosteroids in combination with vitamin D analogues, similar to the treatment for mild and moderate disease. However, in this situation emollients were reported as the second most often used therapy (Table 3) . Data also show that combination therapy of two or more topicals was most frequently used in situations with BSA between 3% and 10%. In this situation, the total percentage of respondents who answered that they 'often' or 'always' use combination therapy of two or more topicals was 65.1% compared to 39.5% when BSA is <3% and 46.5% when BSA is >10%. In the latter situation, 20.9% of respondents answered that they 'never' use this combination (Fig. 2) .
In addition, the data demonstrated that the frequency in which combination therapy of a topical drug and a systemic drug was used increases with increasing disease severity (BSA). In situations with BSA > 10%, the total percentage of respondents who answered that they 'often' or 'always' use combination therapy of a topical drug and a systemic drug was 76.7% compared to 39.6% when BSA is between 3% and 10%, and only 9.4% when BSA is <3%. A subset of respondents (27.9%) answered that they 'never' use combination therapy of a topical drug and a systemic drug in situations with BSA < 3% (Fig. 3) . No apparent association with country or region was found.
To find the most frequently used combination of a topical and a systemic drug, respondents were asked which combination of topicals and systemic drugs they used in certain scenarios.
In situations with BSA between 3% and 10%, we found that among the listed systemics (methotrexate, acitretin, cyclosporine, fumarates, anti-TNF-alpha drugs and ustekinumab), methotrexate and acitretin were most frequently used in combination with a topical drug. In this situation, 83.7% of respondents answered that they use methotrexate in combination with topical corticosteroids making it the most frequently used combination (Table 4) .
In situations with BSA > 10%, the data are inconsistent as variations were found among the topicals. That being said, 93% of respondents answered that they use methotrexate in combination with topical corticosteroids making this the most frequently used combination of a topical and a systemic drug (Table 5) . However, some topicals were only rarely used in combination with a systemic, e.g. when asked which combination of topical retinoids and systemics they use in situations with BSA between Figure 2 Illustrates the percentage using combination therapy of two or more topicals when body surface area (BSA) < 3% (a), when BSA is between 3% and 10% (b) and when BSA is above 10% (c). (c) Figure 3 Illustrates the percentage using combination therapy of a topical and a systemic drug when body surface area (BSA) < 3% (a), when BSA is between 3% and 10% (b) and when BSA is above 10% (c).
3% and 10% and BSA > 10%, respectively, the majority of respondents (86% and 83.7%) answered that this was not relevant, suggesting that they do not use this combination.
Conclusion
In this study, we have conducted a survey among international psoriasis experts in order to describe availability and the use of topical treatments for psoriasis. We found that topical corticosteroids, vitamin D analogues, potent corticosteroids in combination with vitamin D analogues and calcineurin inhibitors were commercially available in almost all countries represented in this survey. Conversely, variation in the availability of therapies such as tars, dithranol (anthralin) and balneotherapy was reported. Furthermore, results showed that topical retinoids are only available in 11 of the 20 countries represented in the survey.
It is important to emphasize that despite being commercially available, it is not given that these topicals are available to all patients in the country. Other determining factors for the possible use of an available drug are presence of physicians and affordability including financing and insurance arrangements. Our results showed that in some countries, all respondents worked in the PHCS, whereas in other countries, the physicians exclusively treated private HI patients (Fig. 1) . This does not necessarily reflect where the average patient is treated, but differences in the healthcare system between countries may obviously influence the affordability of treatment for the individual patient. Acceptability is another determining factor of access to health care which refers to cultural aspects regarding the necessity of care. 8 It defines the type of available and affordable care that will be demanded by the patients. 8, 10 Although acceptability has not been addressed in this survey, this aspect should be taken into consideration in the creation of guidelines and treatment strategies. In addition to investigating the availability of different topical treatments, the questionnaire surveyed the use of topical treatment in different disease severities. The vast majority of respondents (100% and 88.4%) used topical therapy as first-line monotherapy in situations with BSA < 3% and BSA between 3% and 10%, respectively. However, with disease severity increasing to BSA > 10%, the number of respondents who prescribe topical therapy as monotherapy decreased considerably. Furthermore, combination therapy of two or more topicals was most commonly used in situations with BSA between 3% and 10%. Overall, 73.8% respondents reported using potent corticosteroids in combination with a vitamin D analogue. These findings support that in clinical practice, topical therapy is the mainstay in treatment of at least mild to moderate psoriasis. Other studies have also previously shown that even in patients Psoriasis; Access and usage of topical therapy with a BSA of more than 10, topical treatment is used in the majority of patients. 13, 14 The combination of a topical and a systemic drug was most often used when treating patients with a higher burden of disease; 76.7% of respondents answered that they 'often' or 'always' use combination therapy of a topical drug and a systemic drug when BSA is >10%. This suggests that combination therapy of a topical and a systemic drug is frequently used among the dermatologists participating in this survey. Other studies have shown that among patients with a BSA of more than 10%, only a minority of patients are treated with systemic drugs. 14 The high percentage in this survey reporting the use of topical treatment in combination with a systemic drug may be explained by the fact that physicians participating in the survey were all considered psoriasis experts and therefore most likely familiar with the usage of systemic treatment of psoriasis. Only a few published evidence-based studies have examined the efficacy of adding topicals to systemic drug treatments, yet the finding obtained in this survey is not unexpected. Indeed, our findings support the needs recently expressed by Wu et al. 15 for further studies on this matter. In this study, disease severity has been defined according to BSA. Using BSA to define disease severity may not necessarily reflect the patient's perception of disease severity. 14, 16 It has previously been shown that among patients with a BSA of 3 or below, 22% of the patients reported they had severe psoriasis.
14 In addition, a substantial burden of disease severity can also be attributed to psoriasis treatment. 17, 18 Thus, treatment adherence is often a challenge as demonstrated in reports that up to 50% of prescriptions for topical therapies are never filled. 19 Although psoriasis patients have diverse treatment preferences that are difficult to predict, it may be important to identify factors that affect patient preferences in order to improve adherence. A recent study reported that a range of topical formulations should be available to the patient to support treatment adherence. 20 Additional surveys may be important to assess global views on treatment availability and identify current treatment practices that are used by physicians across different countries.
The main limitation of this study is the low and unequally distributed number of respondents representing only a minority of global and regions and countries. This limitation restricts the analysis for cross-regional variations and adds uncertainty to the results. However, all respondents are considered experts on psoriasis treating between 15 and 300 psoriasis patients per month. They represent the specialists within each country and are expected to have a broad and updated knowledge on the subject.
It should be recognized that 42 of the 43 respondents were dermatologists. But it is important to remember that general practitioners (GPs) in many countries play an important role in the treatment of psoriasis patients, especially in patients with mild to moderate disease where topicals are the mainstay in the treatment. A survey among non-psoriasis experts and GP's seems therefore also warranted.
Summary
Psoriasis has a significant impact on quality of life and the psychosocial well-being of the patient and requires an optimal management plan. Generally, topical therapies are well tolerated and effective; however, treatment choice and adherence are critical factors in successful management for each individual. Although the global landscape of topical therapy differs with respect to availability of certain therapies (i.e. retinoids) depending on country, topical treatment remains a gold standard of care for mild to moderate psoriasis. In addition, combination therapy of a topical drug and a systemic drug when BSA is >10% is a common practice. The results presented in this study provide knowledge on the global use of topicals and the influence of disease severity on treatment. Future discussions regarding the position of topicals in psoriasis treatment regimes, both localized and generalized, are needed to advance patient care and to develop international topical treatment consensus guidelines.
